CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023 Report Download

“CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.

“CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023” report highlights:

* Market Opportunity Assessment: More than US$ 60 Billion by 2023
* Clinical and Patent Insight on 17 Commercialize CD Antigen Drugs
* Clinical and Licensing Insight on 184 CD Antigens in Clinical Pipeline
* Dosage and Price Analysis on Key Drugs
* Mechanism of CD Antigen Cancer Therapeutics
* Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
* Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-cd-antigen-cancer-therapy-market-outlook-and-clinical-trials-insight-2023.php

Table of Contents

1. Introduction to CD Antigen Based Cancer Therapeutics
1.1 Prologue to CD Antigens
1.2 Background: Discovering CD Antigens in Cancer Therapy
1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells
2.1 CD Antigens in Normal Cells
2.2 CD Antigens in Cancer

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens
4.1 Monoclonal Antibodies
4.2 Antibody Drug Conjugates
4.3 Bispecific Antibodies

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics
5.1 CAR-T Cell Therapy
5.2 Aptamers
5.3 Immunoconjugates
5.3.1 Radio Immunoconjugate
5.3.2 Toxin Immunoconjugate
5.4 Novel CD Antigen Based Antibodies
5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)
5.4.2 DART and TandAb

6. Major CD Antigens as Targets for Cancer Therapy
6.1 CD20
6.2 CD19
6.3 CD137
6.4 CD38
6.5 CD70
6.6 CD22
6.7 CD30
6.8 CD33
6.9 CD37

7. Major CD Antigens as Cancer Diagnostic Agents
7.1 CD20
7.2 CD5
7.3 CD56
7.4 CD66e
7.5 CD15
7.6 CD30
7.7 CD3

8. Major CD Antigens in Cancer Research
8.1 CD34
8.2 CD10
8.3 CD26
8.4 CD117
8.5 CD44
8.6 CD57

9. Global CD Antigen Based Therapeutics Market Overview
9.1 Market Progression
9.2 Current Market Scenario
9.3 Global CD Antigen Based Cancer Therapeutics Market Trends
9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview

10. Price and Dosage Analysis of Major CD Antigen Based Cancer Therapies
10.1 Rituximab (CD20)
10.2 Ofatumumab (CD20)
10.3 Obinutuzumab (CD20)
10.4 Daratumumab (CD38)
10.5 Brentuximab Vedotin (CD30)
10.6 Gemtuzumab Ozogamicin (CD33)
10.7 Inotuzumab Ozogamicin (CD22)
10.8 Ibritumomab Tiuxetan (CD20)
10.9 Blinatumomab (CD19, CD3)
10.10 Tisagenlecleucel (CD19)

11. Marketed Cancer CD Antigen Inhibitors Clinical and Patent Insight
11.1 Rituximab (MabThera and Rituxan)
11.2 Obinutuzumab (Gazyva and Gazyvaro)
11.3 Ibritumomab Tiuxetan (Zevalin and Zevamab)
11.4 Rituximab Biosimilar (AcellBia and USMAL)
11.5 Rituximab Biosimilar (Reditux and Tidecron)
11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima and Tuxella)
11.7 Rituximab Biosimilar (Novex)
11.8 Rituximab Biosimilar (RituxiRel, Toritz and Toritz RA)
11.9 Rituximab Biosimilar (Maball)
11.10 Rituximab Biosimilar (Kikuzubam)
11.11 Rituximab Biosimilar (Mabtas)
11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat and Remniq)
11.13 Avelumab (BAVENCIO)
11.14 Pembrolizumab (Keytruda)
11.15 Atezolizumab (TECENTRIQ)
11.16 Durvalumab (Imfinzi)
11.17 Rituximab Biosimilar (Zytux)

12. Global CD Antigen Cancer Therapy Market Dynamics
12.1 Market Growth Drivers
12.1.1 Large Patient Base
12.1.2 Unmet Medical Need
12.1.3 Better Safety Profile
12.1.4 Accelerated Research and Development: Newly Identified CD Antigens in Cancer
12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market
12.1.6 Strong Clinical Pipeline
12.2 CD Antigen Market Challenges
12.2.1 High Prices of CD Antigen Based Cancer Therapeutics
12.2.2 Difficulties in Differentiating CD Target on Cancer Cells
12.2.3 High Production Cost Due to Complex Structure

13. Global CD Antigens Cancer Therapy Market Future Forecast

14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I

15. Cancer CD 3 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-II

16. Cancer CD 4 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
16.1 Phase-I

17. Cancer CD 7 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
17.1 Preclinical

18. Cancer CD 19 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
18.1 Phase-I
18.2 Phase-I/II
18.3 Phase-II
18.4 Phase-III

19. Cancer CD 20 Antigen Inhibiors Clinical Pipeline by Company, Indication and Phase
19.1 Unknown
19.2 Research
19.3 Preclinical
19.4 Clinical
19.5 Phase-I
19.6 Phase-I/II
19.7 Phase-II
19.8 Phase-III
19.9 Registered

20. Cancer CD 22 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
20.1 Preclinical
20.2 Phase-III
20.3 Registered

21. Cancer CD 26 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
21.1 Preclinical
21.2 Phase-I/II

22. Cancer CD 27 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
22.1 Research
22.2 Preclinical
22.3 Phase-II

23. Cancer CD 30 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
23.1 Phase-I

24. Cancer CD 33 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
24.1 Phase-I
24.2 Phase-I/II

25. Cancer CD 38 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
25.1 Research
25.2 Preclinical
25.3 Phase-I/II
25.4 Phase-III

26. Cancer CD 44 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
26.1 Preclinical
26.2 Phase-I

27. Cancer CD 45 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
27.1 Phase-III

28. Cancer CD 46 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
28.1 Research

29. Cancer CD 47 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II


30. Cancer CD 52 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
30.1 Research
30.2 Preclinical

31. Cancer CD 55 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
31.1 Preclinical
31.2 Phase-II

32. Cancer CD 56 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
32.1 Phase-II

33. Cancer CD 66 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
33.1 Phase-I

34. Cancer CD 70 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
34.1 Phase-II

35. Cancer CD 71 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
35.1 Preclinical

36. Cancer CD 98 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
36.1 Phase-I

37. Cancer CD 200 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
37.1 Preclinical
37.2 Clinical
37.3 Phase-II

38. Cancer CD 223 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
38.1 Preclinical
38.2 Phase-I
38.3 Phase-I/II
38.4 Phase-II

39. Cancer CD 248 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
39.1 Preclinical
39.2 Phase-II

40. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
40.1 Research
40.2 Preclinical
40.3 Clinical
40.4 Phase-I
40.5 Phase-I/II

41. Cancer CD 319 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
41.1 Phase-I

42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
42.1 Preclinical
42.2 Phase-I
42.3 Phase-I/II
43. Competitive Landscape
43.1 AryoGen Biopharma
43.2 Biocad
43.3 Biogen Idec
43.4 Celltrion
43.5 Genentech
43.6 Genmab
43.7 GLYCART Biotechnology
43.8 Hetero Drugs
43.9 mAbxience
43.10 MedImmune
43.11 Merck
43.12 Sandoz
43.13 UCB

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.